Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, kanamycin and bekanamycin derivatives (obtained from Streptomyces kanamyceticus) | 157 | 37517-28-5 |
Dose | Unit | Route |
---|---|---|
1 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 98 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 25.61 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.16 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.88 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.40 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 22, 1981 | FDA | APOTHECON |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug resistance | 263.98 | 19.32 | 111 | 10486 | 17257 | 46658208 |
Pathogen resistance | 156.80 | 19.32 | 57 | 10540 | 6003 | 46669462 |
Drug reaction with eosinophilia and systemic symptoms | 132.79 | 19.32 | 83 | 10514 | 29465 | 46646000 |
Septic shock | 128.85 | 19.32 | 106 | 10491 | 57787 | 46617678 |
Multiple organ dysfunction syndrome | 128.50 | 19.32 | 101 | 10496 | 51609 | 46623856 |
Deafness | 114.64 | 19.32 | 61 | 10536 | 16007 | 46659458 |
Ototoxicity | 100.50 | 19.32 | 27 | 10570 | 1042 | 46674423 |
Dysphonia | 84.70 | 19.32 | 70 | 10527 | 38344 | 46637121 |
Thrombocytopenia | 83.56 | 19.32 | 122 | 10475 | 126459 | 46549006 |
Klebsiella infection | 79.69 | 19.32 | 36 | 10561 | 6626 | 46668839 |
Geotrichum infection | 79.51 | 19.32 | 19 | 10578 | 453 | 46675012 |
Systemic candida | 75.59 | 19.32 | 27 | 10570 | 2700 | 46672765 |
Toxic skin eruption | 74.45 | 19.32 | 42 | 10555 | 12345 | 46663120 |
Mycobacterium abscessus infection | 74.18 | 19.32 | 19 | 10578 | 607 | 46674858 |
Pseudomonas infection | 72.29 | 19.32 | 38 | 10559 | 9720 | 46665745 |
Eosinophilia | 66.81 | 19.32 | 46 | 10551 | 19171 | 46656294 |
Sepsis | 64.81 | 19.32 | 113 | 10484 | 135901 | 46539564 |
Rash maculo-papular | 61.86 | 19.32 | 51 | 10546 | 27823 | 46647642 |
Tinnitus | 60.09 | 19.32 | 50 | 10547 | 27623 | 46647842 |
Aphonia | 59.02 | 19.32 | 31 | 10566 | 7914 | 46667551 |
Febrile neutropenia | 54.98 | 19.32 | 86 | 10511 | 94541 | 46580924 |
Nephropathy toxic | 52.30 | 19.32 | 28 | 10569 | 7426 | 46668039 |
Myelosuppression | 51.44 | 19.32 | 28 | 10569 | 7675 | 46667790 |
Acute kidney injury | 51.41 | 19.32 | 143 | 10454 | 235712 | 46439753 |
Toxic epidermal necrolysis | 49.93 | 19.32 | 41 | 10556 | 22237 | 46653228 |
Hepatotoxicity | 49.81 | 19.32 | 43 | 10554 | 24966 | 46650499 |
Paradoxical drug reaction | 49.23 | 19.32 | 19 | 10578 | 2357 | 46673108 |
Haemoptysis | 48.10 | 19.32 | 43 | 10554 | 26146 | 46649319 |
Hepatocellular injury | 47.47 | 19.32 | 45 | 10552 | 29477 | 46645988 |
Mycobacterium avium complex infection | 47.23 | 19.32 | 19 | 10578 | 2629 | 46672836 |
Pain | 46.95 | 19.32 | 25 | 10572 | 476923 | 46198542 |
Encephalopathy | 46.18 | 19.32 | 47 | 10550 | 33542 | 46641923 |
Enterococcal infection | 45.55 | 19.32 | 25 | 10572 | 6962 | 46668503 |
Pyrexia | 44.22 | 19.32 | 176 | 10421 | 348626 | 46326839 |
Bronchopulmonary aspergillosis | 43.91 | 19.32 | 25 | 10572 | 7471 | 46667994 |
Fatigue | 43.10 | 19.32 | 45 | 10552 | 608652 | 46066813 |
Candida infection | 41.80 | 19.32 | 37 | 10560 | 22203 | 46653262 |
Osteomyelitis bacterial | 39.40 | 19.32 | 9 | 10588 | 175 | 46675290 |
Acinetobacter infection | 39.11 | 19.32 | 14 | 10583 | 1408 | 46674057 |
Immune reconstitution inflammatory syndrome | 38.75 | 19.32 | 21 | 10576 | 5704 | 46669761 |
Bacteraemia | 38.00 | 19.32 | 29 | 10568 | 14150 | 46661315 |
Off label use | 36.92 | 19.32 | 177 | 10420 | 379664 | 46295801 |
Product use in unapproved indication | 36.60 | 19.32 | 70 | 10527 | 90203 | 46585262 |
Acute respiratory distress syndrome | 36.36 | 19.32 | 34 | 10563 | 21888 | 46653577 |
Fall | 35.79 | 19.32 | 15 | 10582 | 329082 | 46346383 |
Clostridium difficile colitis | 35.13 | 19.32 | 31 | 10566 | 18522 | 46656943 |
Multiple-drug resistance | 34.33 | 19.32 | 15 | 10582 | 2550 | 46672915 |
Mycobacterial infection | 33.62 | 19.32 | 13 | 10584 | 1620 | 46673845 |
Nosocomial infection | 33.61 | 19.32 | 13 | 10584 | 1622 | 46673843 |
Arthralgia | 33.14 | 19.32 | 21 | 10576 | 364582 | 46310883 |
Sputum increased | 32.71 | 19.32 | 13 | 10584 | 1743 | 46673722 |
Mucormycosis | 32.62 | 19.32 | 14 | 10583 | 2278 | 46673187 |
Cholestasis | 32.27 | 19.32 | 35 | 10562 | 26858 | 46648607 |
Acute generalised exanthematous pustulosis | 31.47 | 19.32 | 22 | 10575 | 9383 | 46666082 |
Hepatitis | 30.34 | 19.32 | 37 | 10560 | 32178 | 46643287 |
Herpes simplex hepatitis | 30.15 | 19.32 | 8 | 10589 | 294 | 46675171 |
Hypertransaminasaemia | 29.93 | 19.32 | 15 | 10582 | 3473 | 46671992 |
Retinal ischaemia | 29.74 | 19.32 | 8 | 10589 | 310 | 46675155 |
Haemorrhage intracranial | 29.73 | 19.32 | 24 | 10573 | 12700 | 46662765 |
Neutropenic colitis | 29.70 | 19.32 | 13 | 10584 | 2219 | 46673246 |
Antithrombin III | 29.01 | 19.32 | 7 | 10590 | 174 | 46675291 |
Leukopenia | 27.70 | 19.32 | 53 | 10544 | 68290 | 46607175 |
Hepatosplenic candidiasis | 27.56 | 19.32 | 7 | 10590 | 216 | 46675249 |
Pancreatitis acute | 27.47 | 19.32 | 31 | 10566 | 24841 | 46650624 |
Neutropenia | 27.43 | 19.32 | 83 | 10514 | 143121 | 46532344 |
Cough | 27.35 | 19.32 | 114 | 10483 | 230135 | 46445330 |
Headache | 26.90 | 19.32 | 42 | 10555 | 478310 | 46197155 |
Klebsiella bacteraemia | 26.51 | 19.32 | 10 | 10587 | 1166 | 46674299 |
Granulomatous liver disease | 26.03 | 19.32 | 9 | 10588 | 817 | 46674648 |
Coagulopathy | 25.63 | 19.32 | 26 | 10571 | 18473 | 46656992 |
Granulomatosis with polyangiitis | 25.63 | 19.32 | 11 | 10586 | 1791 | 46673674 |
Dysbiosis | 25.52 | 19.32 | 8 | 10589 | 534 | 46674931 |
Vulvovaginitis | 25.36 | 19.32 | 7 | 10590 | 299 | 46675166 |
Polyneuropathy | 25.18 | 19.32 | 21 | 10576 | 11623 | 46663842 |
Rhinocerebral mucormycosis | 24.72 | 19.32 | 6 | 10591 | 153 | 46675312 |
Kussmaul respiration | 24.72 | 19.32 | 6 | 10591 | 153 | 46675312 |
Pancytopenia | 24.08 | 19.32 | 57 | 10540 | 85001 | 46590464 |
Chemotherapeutic drug level increased | 23.82 | 19.32 | 6 | 10591 | 179 | 46675286 |
Deafness neurosensory | 23.70 | 19.32 | 14 | 10583 | 4480 | 46670985 |
Hyperlactacidaemia | 23.45 | 19.32 | 11 | 10586 | 2204 | 46673261 |
Corneal opacity | 23.38 | 19.32 | 8 | 10589 | 704 | 46674761 |
Febrile bone marrow aplasia | 22.84 | 19.32 | 16 | 10581 | 6846 | 46668619 |
Mycobacterium chelonae infection | 22.68 | 19.32 | 7 | 10590 | 444 | 46675021 |
Overgrowth fungal | 22.64 | 19.32 | 5 | 10592 | 83 | 46675382 |
Nasopharyngitis | 22.33 | 19.32 | 4 | 10593 | 153994 | 46521471 |
Neonatal respiratory distress syndrome | 22.05 | 19.32 | 11 | 10586 | 2522 | 46672943 |
Pain in extremity | 22.00 | 19.32 | 16 | 10581 | 258664 | 46416801 |
Guillain-Barre syndrome | 21.97 | 19.32 | 12 | 10585 | 3310 | 46672155 |
Agranulocytosis | 21.74 | 19.32 | 26 | 10571 | 22159 | 46653306 |
Retinal artery occlusion | 21.40 | 19.32 | 9 | 10588 | 1393 | 46674072 |
Product administered to patient of inappropriate age | 21.40 | 19.32 | 11 | 10586 | 2685 | 46672780 |
Acute hepatic failure | 20.96 | 19.32 | 21 | 10576 | 14700 | 46660765 |
Endocarditis candida | 20.78 | 19.32 | 4 | 10593 | 32 | 46675433 |
Malaise | 20.64 | 19.32 | 27 | 10570 | 331205 | 46344260 |
Infective pulmonary exacerbation of cystic fibrosis | 20.34 | 19.32 | 18 | 10579 | 10789 | 46664676 |
Bone marrow failure | 20.10 | 19.32 | 29 | 10568 | 29640 | 46645825 |
Electrocardiogram QT prolonged | 19.81 | 19.32 | 39 | 10558 | 51286 | 46624179 |
Lower respiratory tract infection bacterial | 19.78 | 19.32 | 6 | 10591 | 359 | 46675106 |
Tinea versicolour | 19.47 | 19.32 | 4 | 10593 | 46 | 46675419 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Ototoxicity | 215.87 | 17.97 | 60 | 13070 | 1336 | 29938012 |
Drug resistance | 210.37 | 17.97 | 123 | 13007 | 20010 | 29919338 |
Septic shock | 173.30 | 17.97 | 174 | 12956 | 63433 | 29875915 |
Pathogen resistance | 105.63 | 17.97 | 58 | 13072 | 8352 | 29930996 |
Product use in unapproved indication | 105.51 | 17.97 | 145 | 12985 | 73548 | 29865800 |
Mycobacterium abscessus infection | 103.55 | 17.97 | 28 | 13102 | 560 | 29938788 |
Deafness | 92.02 | 17.97 | 57 | 13073 | 10268 | 29929080 |
Drug reaction with eosinophilia and systemic symptoms | 88.79 | 17.97 | 84 | 13046 | 28404 | 29910944 |
Multiple organ dysfunction syndrome | 82.06 | 17.97 | 119 | 13011 | 63368 | 29875980 |
Thrombocytopenia | 67.37 | 17.97 | 170 | 12960 | 136874 | 29802474 |
Fatigue | 63.17 | 17.97 | 31 | 13099 | 320642 | 29618706 |
Mycobacterium chelonae infection | 62.44 | 17.97 | 19 | 13111 | 586 | 29938762 |
Acute kidney injury | 61.74 | 17.97 | 260 | 12870 | 273582 | 29665766 |
Rash maculo-papular | 60.89 | 17.97 | 65 | 13065 | 25353 | 29913995 |
Electrocardiogram QT prolonged | 59.66 | 17.97 | 76 | 13054 | 35759 | 29903589 |
Fall | 58.41 | 17.97 | 6 | 13124 | 181866 | 29757482 |
Drug ineffective | 57.50 | 17.97 | 297 | 12833 | 340090 | 29599258 |
Toxic skin eruption | 53.73 | 17.97 | 42 | 13088 | 10973 | 29928375 |
Enterococcal infection | 50.49 | 17.97 | 36 | 13094 | 8188 | 29931160 |
Brain abscess | 49.59 | 17.97 | 24 | 13106 | 2657 | 29936691 |
Tuberculosis | 48.77 | 17.97 | 35 | 13095 | 8042 | 29931306 |
Febrile bone marrow aplasia | 44.16 | 17.97 | 33 | 13097 | 8064 | 29931284 |
Death | 43.41 | 17.97 | 56 | 13074 | 357227 | 29582121 |
Deafness neurosensory | 43.00 | 17.97 | 21 | 13109 | 2372 | 29936976 |
Candida infection | 41.66 | 17.97 | 42 | 13088 | 15320 | 29924028 |
Blood pressure measurement | 39.80 | 17.97 | 10 | 13120 | 148 | 29939200 |
Acute respiratory distress syndrome | 39.40 | 17.97 | 50 | 13080 | 23422 | 29915926 |
Multiple-drug resistance | 38.90 | 17.97 | 21 | 13109 | 2920 | 29936428 |
Hepatotoxicity | 37.56 | 17.97 | 43 | 13087 | 18102 | 29921246 |
Nocardiosis | 35.75 | 17.97 | 21 | 13109 | 3434 | 29935914 |
Aspergillus infection | 35.44 | 17.97 | 32 | 13098 | 10182 | 29929166 |
Deafness bilateral | 33.87 | 17.97 | 14 | 13116 | 1068 | 29938280 |
Hypertransaminasaemia | 33.47 | 17.97 | 21 | 13109 | 3864 | 29935484 |
Pain | 33.43 | 17.97 | 17 | 13113 | 172624 | 29766724 |
Pseudomonas infection | 32.80 | 17.97 | 31 | 13099 | 10451 | 29928897 |
Immune reconstitution inflammatory syndrome | 32.54 | 17.97 | 29 | 13101 | 9072 | 29930276 |
Pyrexia | 32.32 | 17.97 | 230 | 12900 | 294259 | 29645089 |
Treatment failure | 32.29 | 17.97 | 56 | 13074 | 34623 | 29904725 |
Myocardial infarction | 31.72 | 17.97 | 8 | 13122 | 125617 | 29813731 |
Myelosuppression | 31.62 | 17.97 | 26 | 13104 | 7296 | 29932052 |
Acute generalised exanthematous pustulosis | 31.37 | 17.97 | 24 | 13106 | 6074 | 29933274 |
Vascular pseudoaneurysm thrombosis | 31.14 | 17.97 | 7 | 13123 | 62 | 29939286 |
Cholestasis | 31.06 | 17.97 | 46 | 13084 | 24904 | 29914444 |
Leukopenia | 31.06 | 17.97 | 73 | 13057 | 56086 | 29883262 |
Acoustic neuroma | 31.03 | 17.97 | 8 | 13122 | 132 | 29939216 |
Nephropathy toxic | 30.53 | 17.97 | 30 | 13100 | 10609 | 29928739 |
Hepatocellular injury | 30.34 | 17.97 | 46 | 13084 | 25425 | 29913923 |
Off label use | 29.87 | 17.97 | 199 | 12931 | 249091 | 29690257 |
Eosinophilia | 29.25 | 17.97 | 42 | 13088 | 22118 | 29917230 |
Hypoacusis | 28.41 | 17.97 | 33 | 13097 | 14106 | 29925242 |
Hypofibrinogenaemia | 28.25 | 17.97 | 14 | 13116 | 1631 | 29937717 |
Inflammatory marker increased | 26.88 | 17.97 | 17 | 13113 | 3171 | 29936177 |
Mycobacterium avium complex infection | 26.80 | 17.97 | 16 | 13114 | 2695 | 29936653 |
Klebsiella infection | 26.74 | 17.97 | 23 | 13107 | 6864 | 29932484 |
Pancytopenia | 26.70 | 17.97 | 90 | 13040 | 84962 | 29854386 |
Lymphocyte count decreased | 26.45 | 17.97 | 37 | 13093 | 19018 | 29920330 |
Drug ineffective for unapproved indication | 26.35 | 17.97 | 28 | 13102 | 10852 | 29928496 |
Linear IgA disease | 25.65 | 17.97 | 13 | 13117 | 1589 | 29937759 |
Incision site pain | 25.65 | 17.97 | 14 | 13116 | 1990 | 29937358 |
Red blood cells urine positive | 25.53 | 17.97 | 13 | 13117 | 1604 | 29937744 |
Stenotrophomonas infection | 25.48 | 17.97 | 13 | 13117 | 1611 | 29937737 |
Cardiac valve vegetation | 25.30 | 17.97 | 9 | 13121 | 456 | 29938892 |
Bronchopulmonary aspergillosis | 25.23 | 17.97 | 29 | 13101 | 12255 | 29927093 |
Hyperbilirubinaemia | 25.18 | 17.97 | 34 | 13096 | 16908 | 29922440 |
Protein urine present | 25.01 | 17.97 | 19 | 13111 | 4756 | 29934592 |
Sepsis | 24.71 | 17.97 | 128 | 13002 | 146267 | 29793081 |
Systemic candida | 23.96 | 17.97 | 15 | 13115 | 2749 | 29936599 |
Posterior reversible encephalopathy syndrome | 23.96 | 17.97 | 24 | 13106 | 8683 | 29930665 |
Candida sepsis | 23.90 | 17.97 | 11 | 13119 | 1088 | 29938260 |
Mycobacterium fortuitum infection | 23.58 | 17.97 | 7 | 13123 | 198 | 29939150 |
Toxic neuropathy | 23.12 | 17.97 | 8 | 13122 | 373 | 29938975 |
Weight bearing difficulty | 23.00 | 17.97 | 10 | 13120 | 865 | 29938483 |
Respiratory distress | 22.92 | 17.97 | 47 | 13083 | 32925 | 29906423 |
Allodynia | 22.59 | 17.97 | 9 | 13121 | 624 | 29938724 |
Agranulocytosis | 22.50 | 17.97 | 37 | 13093 | 21905 | 29917443 |
Disseminated intravascular coagulation | 22.21 | 17.97 | 37 | 13093 | 22134 | 29917214 |
Sepsis neonatal | 21.89 | 17.97 | 7 | 13123 | 255 | 29939093 |
Sputum purulent | 21.75 | 17.97 | 8 | 13122 | 446 | 29938902 |
Scedosporium infection | 21.53 | 17.97 | 9 | 13121 | 706 | 29938642 |
Hepatitis fulminant | 21.35 | 17.97 | 16 | 13114 | 3925 | 29935423 |
Dehydration | 21.28 | 17.97 | 14 | 13116 | 123525 | 29815823 |
Aeromonas infection | 21.26 | 17.97 | 7 | 13123 | 280 | 29939068 |
Fusarium infection | 21.12 | 17.97 | 10 | 13120 | 1054 | 29938294 |
Headache | 20.62 | 17.97 | 30 | 13100 | 182276 | 29757072 |
Vestibular disorder | 20.42 | 17.97 | 9 | 13121 | 804 | 29938544 |
Malaise | 20.37 | 17.97 | 26 | 13104 | 166936 | 29772412 |
Cardiac failure congestive | 20.12 | 17.97 | 6 | 13124 | 84401 | 29854947 |
Meningitis tuberculous | 20.05 | 17.97 | 8 | 13122 | 557 | 29938791 |
Dizziness | 19.30 | 17.97 | 35 | 13095 | 194874 | 29744474 |
Product dose omission issue | 19.30 | 17.97 | 8 | 13122 | 91623 | 29847725 |
Mucormycosis | 19.25 | 17.97 | 17 | 13113 | 5251 | 29934097 |
Febrile neutropenia | 19.18 | 17.97 | 95 | 13035 | 106598 | 29832750 |
Gallstone ileus | 19.16 | 17.97 | 4 | 13126 | 24 | 29939324 |
Hepatosplenic candidiasis | 18.96 | 17.97 | 6 | 13124 | 211 | 29939137 |
Shock | 18.82 | 17.97 | 35 | 13095 | 22824 | 29916524 |
Flavobacterium infection | 18.78 | 17.97 | 5 | 13125 | 94 | 29939254 |
Syncope | 18.56 | 17.97 | 7 | 13123 | 84896 | 29854452 |
Acinetobacter infection | 18.55 | 17.97 | 9 | 13121 | 1001 | 29938347 |
Pericarditis tuberculous | 18.44 | 17.97 | 5 | 13125 | 101 | 29939247 |
C-reactive protein increased | 18.30 | 17.97 | 51 | 13079 | 43422 | 29895926 |
Neuropathy peripheral | 18.21 | 17.97 | 70 | 13060 | 70405 | 29868943 |
Fungal sepsis | 18.17 | 17.97 | 8 | 13122 | 713 | 29938635 |
Skin hyperpigmentation | 18.13 | 17.97 | 13 | 13117 | 2981 | 29936367 |
Pulmonary cavitation | 18.12 | 17.97 | 8 | 13122 | 718 | 29938630 |
Renal tubular disorder | 17.99 | 17.97 | 16 | 13114 | 4990 | 29934358 |
Source | Code | Description |
---|---|---|
ATC | D06AX12 | DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE ANTIBIOTICS FOR TOPICAL USE Other antibiotics for topical use |
ATC | J01GB06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE AMINOGLYCOSIDE ANTIBACTERIALS Other aminoglycosides |
ATC | J01RA06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE COMBINATIONS OF ANTIBACTERIALS Combinations of antibacterials |
ATC | S01AA21 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics |
FDA CS | M0000946 | Aminoglycosides |
FDA EPC | N0000175477 | Aminoglycoside Antibacterial |
CHEBI has role | CHEBI:33281 | antibiotics |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
CHEBI has role | CHEBI:61015 | nephrotoxins |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Septicemia due to Escherichia coli | indication | 9323009 | |
Bacterial septicemia | indication | 10001005 | DOID:0040085 |
Infection due to Pseudomonas aeruginosa | indication | 11218009 | |
Staphylococcal meningitis | indication | 12166008 | |
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Staphylococcal pneumonia | indication | 22754005 | |
Pneumonia due to Pseudomonas | indication | 41381004 | |
Pneumonia due to Escherichia coli | indication | 51530003 | |
Bacterial pneumonia | indication | 53084003 | DOID:874 |
Osteomyelitis | indication | 60168000 | |
Infection due to Escherichia coli | indication | 71057007 | |
Bacterial infection due to Serratia | indication | 71120004 | |
Rhinoscleroma | indication | 72409005 | DOID:11336 |
Septicemia due to Serratia | indication | 82091000 | |
Cholangitis | indication | 82403002 | DOID:9446 |
Bacterial meningitis | indication | 95883001 | DOID:9470 |
Infection of bone | indication | 111253001 | |
Staphylococcal septicemia | indication | 111821004 | |
Infectious disease of abdomen | indication | 128070006 | |
Infection due to Enterobacteriaceae | indication | 128945009 | |
Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
Escherichia coli meningitis | indication | 192655005 | |
Proteus pneumonia | indication | 195888009 | |
Sepsis of the newborn | indication | 206376005 | |
Neonatal pneumonia | indication | 233619008 | |
Diverticulitis of gastrointestinal tract | indication | 271366000 | |
Neonatal meningitis | indication | 276674008 | |
Proteus septicemia | indication | 300986008 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus meningitis | indication | 302877009 | |
Bacterial urinary infection | indication | 312124009 | |
Infectious disorder of joint | indication | 363162000 | |
Meningitis due to Klebsiella mobilis | indication | 420585007 | |
Nosocomial pneumonia | indication | 425464007 | |
Bacterial meningitis due to Gram-negative bacteria | indication | 425887005 | |
Pneumonia due to Gram negative bacteria | indication | 430395005 | |
Sepsis due to Pseudomonas | indication | 448813005 | |
Sepsis due to Gram negative bacteria | indication | 449082003 | |
Urinary tract infection caused by Klebsiella | indication | 369001000119100 | |
Skin and Skin Structure Serratia Infection | indication | ||
Pseudomonas Aeruginosa Biliary Tract Infection | indication | ||
Klebsiella Septicemia | indication | ||
Complicated Urinary Tract Infections | indication | ||
Complicated UTI with Pseudomonas Aeruginosa | indication | ||
Pseudomonas Aeruginosa Meningitis | indication | ||
Pseudomonas Aeruginosa Osteomyelitis | indication | ||
Skin and Skin Structure Proteus Infection | indication | ||
Serratia Meningitis | indication | ||
Skin and Skin Structure Staphylococcus Infection | indication | ||
Enterobacter Meningitis | indication | ||
Skin and Skin Structure Pseudomonas Aeruginosa Infection | indication | ||
Burn Wound Infections | indication | ||
Gram-Negative Aerobic Bacillary Pneumonia | indication | ||
Complicated Bacterial Peritonitis | indication | ||
Complicated Proteus UTI | indication | ||
Complicated Urinary Tract Infection due to Acinetobacter | indication | ||
Pseudomonas Aeruginosa Joint Infection | indication | ||
Serratia Osteomyelitis | indication | ||
Serratia Complicated UTI | indication | ||
Enterobacter Pneumonia | indication | ||
Necrotizing enterocolitis in fetus OR newborn | off-label use | 2707005 | |
Pyrexia of unknown origin | off-label use | 7520000 | |
Enteric campylobacteriosis | off-label use | 18081009 | |
Acute tuberculosis | off-label use | 25629007 | |
Pseudotuberculosis | off-label use | 36753006 | |
Infection by Yersinia enterocolitica | off-label use | 80960004 | |
Pulmonary tuberculosis | off-label use | 154283005 | DOID:2957 |
Synergy for Neonatal Meningitis | off-label use | ||
Citrobacter Complicated UTI | off-label use | ||
Synergy for Group B Streptococcal Septicemia | off-label use | ||
Citrobacter Septicemia | off-label use | ||
Citrobacter Meningitis | off-label use | ||
Synergy for Bacterial Meningitis | off-label use | ||
Citrobacter Osteomyelitis | off-label use | ||
Synergy for P. Aeruginosa Infection in Cystic Fibrosis | off-label use | ||
Listeria Monocytogenes Septicemia | off-label use | ||
Skin and Skin Structure Citrobacter Infection | off-label use | ||
Skin and Skin Structure Acinetobacter Infection | off-label use | ||
Synergy for Staphylococcal Infections | off-label use | ||
Citrobacter Pneumonia | off-label use | ||
Synergy for Nosocomial Pneumonia due to Pseudomonas Aeruginosa | off-label use | ||
Synergy for Staphylococcal Endocarditis | off-label use | ||
Hypocalcemia | contraindication | 5291005 | |
Parkinsonism | contraindication | 32798002 | |
Dehydration | contraindication | 34095006 | |
Tinnitus | contraindication | 60862001 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Myasthenia gravis | contraindication | 91637004 | DOID:437 |
Pregnancy, function | contraindication | 289908002 | |
Vertigo | contraindication | 399153001 | |
Disorder of the 8th Cranial Nerve | contraindication | ||
Amikacin Toxicity | contraindication | ||
Infant Botulism | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 12.04 | acidic |
pKa2 | 12.95 | acidic |
pKa3 | 13.39 | acidic |
pKa4 | 13.72 | acidic |
pKa5 | 9.4 | Basic |
pKa6 | 7.84 | Basic |
pKa7 | 7.41 | Basic |
pKa8 | 6.86 | Basic |
None
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 590MG BASE/8.4ML | ARIKAYCE KIT | INSMED INC | N207356 | Sept. 28, 2018 | RX | SUSPENSION, LIPOSOMAL | INHALATION | Sept. 28, 2025 | TX OF MAC LUNG DISEASE IN ADULTS WITH LIMITED OR NO ALTERNULLTIVE TX OPTIONS AS PART OF A COMBO ANTIBACTERIAL DRUG REGIMEN WHO DO NOT ACHIEVE NEGATIVE SPUTUM CULTURES AFTER A MINIMUM OF 6 CONSECUTIVE MONTHS OF A MULTIDRUG BACKGROUND REGIMEN THERAPY |
EQ 590MG BASE/8.4ML | ARIKAYCE KIT | INSMED INC | N207356 | Sept. 28, 2018 | RX | SUSPENSION, LIPOSOMAL | INHALATION | Sept. 28, 2030 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B) | Enzyme | Km | 4.20 | WOMBAT-PK |
ID | Source |
---|---|
84319SGC3C | UNII |
4019602 | VUID |
N0000147698 | NUI |
D00865 | KEGG_DRUG |
39831-55-5 | SECONDARY_CAS_RN |
C0002499 | UMLSCUI |
CHEBI:2637 | CHEBI |
AKN | PDB_CHEM_ID |
CHEMBL177 | ChEMBL_ID |
CHEMBL1164318 | ChEMBL_ID |
CHEMBL4208954 | ChEMBL_ID |
DB00479 | DRUGBANK_ID |
D000583 | MESH_DESCRIPTOR_UI |
37768 | PUBCHEM_CID |
3492 | INN_ID |
10894 | IUPHAR_LIGAND_ID |
641 | RXNORM |
2863 | MMSL |
35287 | MMSL |
4165 | MMSL |
d00087 | MMSL |
002781 | NDDF |
004899 | NDDF |
1269009 | SNOMEDCT_US |
387266001 | SNOMEDCT_US |
48836000 | SNOMEDCT_US |
4018137 | VANDF |
4019602 | VANDF |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Amikacin Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6166 | INJECTION | 250 mg | INTRAMUSCULAR | ANDA | 22 sections |
Amikacin Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6167 | INJECTION | 250 mg | INTRAMUSCULAR | ANDA | 22 sections |
Amikacin Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-9032 | INJECTION, SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 20 sections |
Amikacin Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-9040 | INJECTION, SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 20 sections |
Amikacin Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-290 | INJECTION, SOLUTION | 250 mg | INTRAMUSCULAR | ANDA | 20 sections |
Amikacin Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-785 | INJECTION, SOLUTION | 500 mg | INTRAMUSCULAR | ANDA | 20 sections |
Amikacin Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-786 | INJECTION, SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 20 sections |
amikacin sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-173 | INJECTION, SOLUTION | 250 mg | INTRAVENOUS | ANDA | 23 sections |
Amikacin Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-815 | INJECTION, SOLUTION | 250 mg | INTRAVENOUS | ANDA | 19 sections |
Amikacin Sulfate Injection, 500 mg/2ml | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70297-996 | INJECTION | 500 mg | INTRAMUSCULAR | Export only | |
Amikacin Sulfate Injection, 500 mg/2ml | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71309-996 | INJECTION | 500 mg | INTRAMUSCULAR | Export only | |
ARIKAYCE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71558-590 | SUSPENSION | 590 mg | RESPIRATORY (INHALATION) | NDA | 33 sections |